Dostarlimab and new drug combos before surgery for endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether giving a drug called dostarlimab (an immunotherapy that boosts your immune system to fight cancer) before and after surgery can help treat advanced endometrial cancer. It is for people with stage 3 or 4 endometrial cancer who haven't had treatment yet and may be eligible if their tumor has a specific marker called mismatch repair deficiency.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have stage 3 or stage 4 endometrial cancer that can be surgically removed.
- You must not have had prior treatment (like chemo, radiation, or hormone therapy) for this cancer.
- You must be willing to provide tumor tissue samples from a previous biopsy and a new biopsy, plus tissue during surgery.
- Your cancer must be a specific type called epithelial endometrial cancer (not carcinosarcoma).
- You must be in generally good health, able to do daily activities, and have adequate organ function (like kidney and liver).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding dostarlimab (an immunotherapy medicine) to radiation after surgery can lower cancer returning and improve outcomes. It’s for people with certain endometrial cancers found to have specific genetic/molecular changes and who have stage III/IVA disease after surgery.
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
This trial tests whether an immunotherapy combination can help shrink or control endometrial cancer so that surgery might not be needed. It is for people whose tumors have a specific genetic feature (dMMR/MSI-H) that may respond well to this treatment.
This trial tests a new drug combination (sacituzumab tirumotecan plus pembrolizumab) against pembrolizumab alone for people with a specific type of advanced or recurrent endometrial cancer that has normal mismatch repair function. It aims to see which treatment works better.
This trial tests whether giving the drug dostarlimab before surgery can shrink or control endometrial cancer. It is for people whose tumors have a specific genetic feature (MMR deficiency) that may make the drug more effective.
This trial tests a new drug called dostarlimab, given with standard chemotherapy, for people with advanced or recurrent endometrial cancer. It aims to see if this combination can help shrink tumors or slow their growth.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.